Summary: In cover story of the February 2022 issue of Psychiatric Times, MAPS-sponsored researcher Reid Robison, M.D., M.B.A., provides an approachable overview of the state of psychedelic psychiatry, highlighting the successful results of MAPS’ first Phase 3 clinical trial of MDMA-assisted therapy for PTSD. He also addresses the “unique challenges” and wide-ranging implications ahead as treatments involving psychedelics gain mainstream acceptance.